Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Total Current Liabilities (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Total Current Liabilities readings, the most recent being $376172.0 for Q4 2025.

  • Quarterly Total Current Liabilities fell 52.72% to $376172.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $376172.0 through Dec 2025, down 52.72% year-over-year, with the annual reading at $376172.0 for FY2025, 52.72% down from the prior year.
  • Total Current Liabilities hit $376172.0 in Q4 2025 for Drugs Made In America Acquisition, down from $456611.0 in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $795669.0 in Q4 2024 and bottomed at $301441.0 in Q2 2025.